Hematologic Diseases

• 

  Subject Areas on Research

  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. 
  • A prospective study of the epidemiology of adverse drug reactions in pediatric hematology and oncology patients. 
  • A public health framework for rare blood disorders. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. 
  • An outpatient Urgent Care Bay within a pediatric cancer and hematology center. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. 
  • Bone marrow transplantation for non-malignant disease. 
  • Bone marrow transplantation in the perinatal period. 
  • Bone marrow transplantation. Part I--Allogeneic. 
  • Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. 
  • Carboplatin pharmacokinetics in young children with brain tumors. 
  • Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity. 
  • Clinical characteristics and outcomes in biclonal gammopathies. 
  • Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. 
  • Clinical use of oral contraceptives administered vaginally: a case report. 
  • Co-occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines. Part II. 
  • Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Detection of iron deficiency in children with Down syndrome. 
  • Detection of platelet isoantibodies by (3H)serotonin platelet release and its clinical application to the problem of platelet matching. 
  • Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. 
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. 
  • Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. 
  • Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. 
  • Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. 
  • Family-directed umbilical cord blood banking. 
  • Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience. 
  • Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. 
  • Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1. 
  • Growth and development after bone marrow transplantation. 
  • Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. 
  • Hematologic disorders and nonimmune hydrops fetalis. 
  • Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy. 
  • Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. 
  • How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures. 
  • Human neutrophil dysfunction with giant granules and defective activation of the respiratory burst. 
  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Immunologic resolution of human chronic graft-versus-host disease. 
  • Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. 
  • Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. 
  • Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review. 
  • Male mice deficient in microsomal epoxide hydrolase are not susceptible to benzene-induced toxicity. 
  • Marrow transplantation for disorders of hematopoiesis. 
  • Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. 
  • Molecular diagnosis of hemoglobinopathies and other red blood cell disorders. 
  • Neurologic manifestations of hematologic disease. 
  • Non-myeloablative umbilical cord blood transplantation. 
  • Nutrition therapy cost analysis in the US: pre-mixed multi-chamber bag vs compounded parenteral nutrition. 
  • Ocular manifestations of hematologic disorders. 
  • Outcomes among 562 recipients of placental-blood transplants from unrelated donors. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • Partial splenectomy before a hematopoietic stem cell transplantation in children. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. 
  • Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Phase II study of etoposide for carcinoma of the prostate. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Phenotypic expansion of KMT2D-related disorder: Beyond Kabuki syndrome. 
  • Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Practical murine hematopathology: a comparative review and implications for research. 
  • Pruritus in systemic disease: mechanisms and management. 
  • Pulmonary mucormycosis: radiologic findings in 32 cases. 
  • Retinal manifestations of oncologic and hematologic conditions. 
  • Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope® registry and from the literature. 
  • Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. 
  • Second marrow infusion for poor graft function after allogeneic marrow transplantation. 
  • Some haematopathological features of marathon running. 
  • Strategic transformation of population studies: recommendations of the working group on epidemiology and population sciences from the National Heart, Lung, and Blood Advisory Council and Board of External Experts. 
  • Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. 
  • Temozolomide in pediatric low-grade glioma. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The cardiofaciocutaneous syndrome. 
  • The clinical value of qualitative peripheral blood leukocyte changes. 
  • The influence of relationships on children's and adolescents' participation in research 
  • The new approach to assignment of ASFA categories--introduction to the fourth special issue: clinical applications of therapeutic apheresis. 
  • Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. 
  • Unrelated donor marrow transplantation in children. 
  • Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • [Hematologic diseases: from within the heart]. 
• 

  Keywords of People

  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology